Company: PBH
Filing Date: 2025-08-07
Form Type: 8-K
Source: 0001295947-25-000027
Chunk: 0

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-08-07
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On August 4, 2025, Medtech Pharma Holdings Limited (“ Purchaser”), an Ontario corporation and a wholly-owned indirect subsidiary of Prestige Consumer Healthcare Inc. (the “ Company”), entered into a definitive agreement (the “ Share Purchase Agreement”) with ANJAC SAS, a French company (“ ANJAC”). The Share Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, Purchaser will acquire all of the shares of Pillar5 Pharma Inc., a Canadian company that is a leading sterile ophthalmic manufacturer and current Clear Eyes® supplier (“ Pillar5”), from ANJAC for CAD 150 million in cash, subject to certain adjustments, including indebtedness, as provided in the Share Purchase Agreement (the “ Transaction”).

The Company expects the Transaction to close in the third quarter of Fiscal 2026.

The closing of the Transaction is subject to the satisfaction or waiver of certain conditions relating to the operational and regulatory state of the Pillar5 factory and other customary conditions to closing.

The Share Purchase Agreement contains customary representations, warranties, and covenants of both Purchaser and ANJAC, as well as indemnification provisions that are subject to specified limitations. Purchaser has obtained representation and warranty insurance, which serves as Purchaser’s sole recourse for losses related to breaches of ANJAC’s representations and warranties, other than in the case of fraud. Subject to certain exceptions and limitations, Purchaser and ANJAC have agreed to indemnify each other for breaches of post-closing covenants, fraud and other specified matters contained in the Share Purchase Agreement.

The Share Purchase Agreement also contains certain customary termination rights for each of Purchaser and ANJAC. The Share Purchase Agreement may be terminated by either Purchaser or ANJAC if the closing of the Transaction has not occurred prior to December 31, 2025, subject to certain exceptions specified in the Share Purchase Agreement. The Share Purchase Agreement may also be terminated by either Purchaser or ANJAC if the other party is in breach of the Share Purchase Agreement, such that it has not met its closing conditions and has not or is not able to cure such breach.

The foregoing description of the terms of the Share Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Share Purchase Agreement. The Company expects to file a copy of the Share Purchase Agreement as an exhibit to its Quarterly Report on Form